Ikeda H, Mariko M, Komatsu M, Takahashi K, Yasui S, Takahashi K
1st Department of Internal Medicine, Yamagata University School of Medicine.
Eur J Nucl Med. 1989;15(10):646-8. doi: 10.1007/BF00251677.
The accumulation of venously injected 123I-IMP in the lung was studied. Between 30 and 50 min after the injection of the 1.5 mCi 123I-IMP, the concentration of 123I-IMP in the broncho-alveolar lavage fluid were much higher than in the blood. It was considered that 123I-IMP was transported into the alveolar spaces and was absorbed by the alveolar cells. The half time (T1/2) of the 123I-IMP release from the lung between 10 and 25 min immediately after the injection was calculated. In normal subjects the T1/2 ranged between 25 and 44 min and was prolonged in subjects with pulmonary fibrosis, sarcoidosis, and allergic alveolitis. It was considered that the retention of 123I-IMP was related not only to the endothelial cells, but also to the alveolar cells. It was considered that the analysis of the lung release of 123I-IMP forms a new lung dysfunction index.
研究了静脉注射123I-IMP后在肺中的蓄积情况。在注射1.5毫居里123I-IMP后的30至50分钟之间，支气管肺泡灌洗液中123I-IMP的浓度远高于血液中的浓度。据认为，123I-IMP被转运到肺泡腔并被肺泡细胞吸收。计算了注射后立即在10至25分钟之间123I-IMP从肺中释放的半衰期（T1/2）。在正常受试者中，T1/2在25至44分钟之间，而在患有肺纤维化、结节病和过敏性肺泡炎的受试者中则延长。据认为，123I-IMP的滞留不仅与内皮细胞有关，而且与肺泡细胞有关。据认为，对123I-IMP肺释放的分析形成了一种新的肺功能障碍指标。
